Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 49 Carcinoma, Renal Cell 30 Neoplasm Metastasis 18 Neoplasms 15 Kidney Neoplasms 14 Neuroendocrine Tumors 11 Carcinoma, Neuroendocrine 9 Prostatic Neoplasms 7 Melanoma 7 Triple Negative Breast Neoplasms 6 Thyroid Neoplasms 6 Sarcoma 6 Meningioma 6 Lymphoma 6 Glioma 6 Endometrial Neoplasms 6 Tuberous Sclerosis 5 Stomach Neoplasms 5 Recurrence 5 Lymphoma, Mantle-Cell 5 Head and Neck Neoplasms 5 Colorectal Neoplasms 5 Carcinoma, Hepatocellular 5 Carcinoma 5 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Lymphoma, Large B-Cell, Diffuse 4 Liver Neoplasms 4 Carcinoma, Islet Cell 4 Astrocytoma 4

Interventions

Megestrol Acetate 5 Tirzepatide 2 Progestins 2 Metformin 2 Biopsy 2 Atorvastatin 2 exemestane 1 estradiol, norethindrone drug combination 1 Rosuvastatin Calcium 1 Pterocarpus marsupium 1 Progesterone 1 Pharmacogenomic Variants 1 Medroxyprogesterone Acetate 1 Levonorgestrel 1 Hysterectomy 1 Hydroxymethylglutaryl-CoA Reductase Inhibitors 1 Everolimus 1 Curettage 1 3,5-dimethoxy-4'-hydroxystilbene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Endometrial Hyperplasia × Everolimus × Clear all

NCT02397083 2026-02-13

LEVER

M.D. Anderson Cancer Center

Phase 2 Active not recruiting

Endometrial Hyperplasia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡